BERGENBIO ASA Bergen, Norway ,29 May 2020 - Notice is hereby given of an Extraordinary General Meeting in BerGenBioASA will be held on19 June 2020 at 15:00 hours (CET) at the Company's offices in Møllendalsbakken 9, 5009 Bergen. The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available at https://www.bergenbio.com/investors/general- meetings/ (https://www.bergenbio.com/investors/general-%20meetings/) Due to COVID-19 related restrictions and the advice from the Norwegian government all shareholders are encouraged to exercise their shareholder rights without physical attendance at the general meeting, either through advance electronically voting throughVPS Investor Services or by using the enclosed proxy form to provide proxy to the ChairmanSveinung Hole (or the person he appoints). Notice of attendance, advance vote or proxy for the Extraordinary General Meeting can be registered through the company's website or VPS Investor Service. All registered shareholders will receive a reference number and a pin code required for registration through the company's website. Reference number and pin code will be received either by VPS Investor Service or by post depending if the shareholder is registered as electronical user. We encourage all shareholders to register as electronical user in VPS to save environment impact. -Ends- ContactsRichard Godfrey CEO,BerGenBio ASA +47 917 86 304Rune Skeie , CFO,BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513 AboutBerGenBio BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers and infectious diseases. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapyin lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel,BerGenBio is developing companion diagnostic tests to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine -based commercialisation strategy.BerGenBio is based in Bergen, Norway with a subsidiary in Oxford,UK . The company is listed on theOslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source
